ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1359

M-DAS28, M-SDAI and M-CDAI Performance in a Cohort of RA Patients with and without Concomitant Fibromyalgia

Julia Sosa1, Silvana Karina Pérez1, Maria Julia Santa Cruz1, María Alejandra Medina1, Silvia Beatriz Papasidero1, Diana Klajn2, Jose Angel Caracciolo1, María de los Angeles Correa3, Roger Rolón4, Gustavo Citera4, Maria Constanza Bertolaccini5, LL Gonzalez6, L Vargas7 and Oscar Rillo7, 1Rheumatology Department, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, 2Research Committee, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, 3Section Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Buenos Aires, Argentina, 4Rheumatology Department, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 5Rheumatology, Hospital Angel Cruz Padilla, Tucumán, Argentina, 6Hospital Angel Cruz Padilla, Tucumán, Argentina, 7Rheumatology Department, Hospital General de Agudos Dr. Ignacio Pirovano, Buenos Aires, Argentina

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: fibromyalgia, outcome measures and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Fibromyalgia has been reported in approximately 20% of Rheumatoid Arthritis (RA) patients. Several studies have shown that the presence of Fibromyalgia (FM) is associated with a significant increase in patient-reported outcomes (PROs). Therefore, traditional composite measures usually employed for the assessment of disease activity in RA, would not be able to discriminate between RA activity and FM symptoms. Baker et al. developed modified disease activity scores based on DAS28, SDAI and CDAI (M-DAS28, M-SDAI, M-CDAI). Interestingly, these scores of which all self-reported measures were excluded, showed a better correlation with synovitis detected on magnetic resonance imaging (MRI). By excluding the tender joint count and the patient’s global assessment of disease activity, these new activity scores would represent a useful tool to better determine RA activity in patients with concomitant FM. The aim of this study was to evaluate the M-DAS28, M-SDAI and M-CDAI performance in a cohort of RA patients with and without concomitant FM. Methods: Cross-sectional observational study that included consecutive patients with diagnosis of RA (ACR/EULAR 2010 criteria) with and without concomitant FM (ACR 1990 and/or ACR 2010 criteria). Other connective tissue disorders (except secondary Sjögren´s Syndrome) were excluded. Demographic and RA characteristics, and disease activity measures were collected. Patients were divided into 2 groups: RA and RA+FM. Statistical analysis: Mean differences between traditional and modified scores in RA patients with and without FM were analyzed. A linear regression model evaluating the effect of FM presence on score difference was performed, adjusting by covariates that proved significant on bivariate analysis. Results: A total of 130 patients were included, 90% women, mean age was 53 years (SD 12.3). Thirty-five patients had RA+FM (27%). Mean duration of RA was 66 months (IQR 23-120). The only difference between the groups with and without FM was the presence of nodular disease (11.4% vs 32.6%, p=0.01). The difference between traditional and modified scores was higher and statistically significant in the RA+FM group (Table 1). This difference remained after adjusting for sex, age and nodular disease (Table 2). Conclusion: RA activity assessed by these new modified disease activity scores in patients with RA and concomitant FM was lower than that measured by traditional ones. Therefore, these new modified scores could avoid a disease activity overestimation in RA patients with FM, resulting in a better tool to achieve the “Treat to Target” premises.


Disclosure: J. Sosa, None; S. K. Pérez, None; M. J. Santa Cruz, None; M. A. Medina, None; S. B. Papasidero, None; D. Klajn, None; J. A. Caracciolo, None; M. D. L. A. Correa, None; R. Rolón, None; G. Citera, Novartis, Pfizer Inc, 2,AbbVie, Bristol-Myers Squibb, Janssen, Novartis, Pfizer Inc, 5; M. C. Bertolaccini, None; L. Gonzalez, None; L. Vargas, None; O. Rillo, None.

To cite this abstract in AMA style:

Sosa J, Pérez SK, Santa Cruz MJ, Medina MA, Papasidero SB, Klajn D, Caracciolo JA, Correa MDLA, Rolón R, Citera G, Bertolaccini MC, Gonzalez L, Vargas L, Rillo O. M-DAS28, M-SDAI and M-CDAI Performance in a Cohort of RA Patients with and without Concomitant Fibromyalgia [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/m-das28-m-sdai-and-m-cdai-performance-in-a-cohort-of-ra-patients-with-and-without-concomitant-fibromyalgia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/m-das28-m-sdai-and-m-cdai-performance-in-a-cohort-of-ra-patients-with-and-without-concomitant-fibromyalgia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology